Ticagrelor may also be used for purposes not listed in this medication guide.
Brilique is a drug made in Argentina, Belgium, Croatia (Hrvatska), Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Greece, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Tunisia, United Kingdom. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Ticagrelor is a complete analogue of Brilique. It has the same composition, dosage and methods of use. Also Ticagrelor has a lower cost compared to Brilique.
To buy Brilique, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
Check with your physician for additional information about side effects. Bleeding gums pounding in the ears Difficult or labored breathing dizziness red or dark brown urine nosebleeds, or any bleeding that will not stop; slow or fast heartbeat fast or irregular heartbeat
Warnings
Tell your doctor if you have ever had:
- a stroke;
- heart problems;
- a surgery or bleeding injury;
- bleeding problems;
- a stomach ulcer or colon polyps;
- liver disease; or
- asthma, COPD (chronic obstructive pulmonary disorder) or other breathing problem.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
You should not breast-feed while using ticagrelor.
Interactions
Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Consider therapy modification
Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Monitor therapy
Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. Monitor therapy
Food interaction
Pregnancy
- Because POPs protect against pregnancy, the chance of having a pregnancy outside the womb is very low.
- The dose will then be adjusted depending on how your baby responds to the treatment.
- If the film coating of the tablet has been broken or the tablet crushed, it should not be handled by a woman who is pregnant or planning to become pregnant.
Overview
- the combined use of ticagrelor and ASA in a high maintenance dose (more than 300 mg) is not recommended;
- with the combined use of ticagrelor with powerful inhibitors of glycoprotein P and moderate inhibitors of the isoenzyme CYP3A4 (for medicated, verapamil and quinidine);
- with the combined use of selective serotonin reuptake inhibitors simple example, paroxetine, sertraline and citalopram);
- with the combined use of digoxin and the Brilint drug, careful clinical and laboratory monitoring is recommended (heart rate, in the presence of clinical indications also of an ECG and digoxin concentration in the blood;
- with the combined use of the drug Brilinta with drugs that affect hemostasis.
Dosage
The drug is taken orally, regardless of food intake.
For patients with difficulty swallowing, the tablet should be crushed to a state of fine powder, mixed in 1/2 cup of drinking water and immediately drink the resulting suspension. Mix the residues with an additional 1/2 cup of drinking water and drink the resulting suspension. The suspension may also be administered via a nasogastric tube (CH8 or larger). After administration of the suspension, it is necessary to rinse the nasogastric tube with water so that the dose of the drug completely enters the patient’s stomach.
Patients with a history of myocardial infarction (myocardial infarction transferred 1 year ago or more) do not require a about dose of Brilint, the recommended dose is 60 mg 2 times / day.
Long-term therapy with Brilint is recommended, except in cases of clinical need for early drug withdrawal. Experience with the use of the drug Brilint at a dose of 60 mg over 3 years in patients with a history of myocardial infarction.
Patients taking Brilint's drug Brilique take ASA daily in a low maintenance dose (75-150 mg), if there are no specific contraindications.
Patients can start therapy with Brilint at a dose of 60 mg 2 times / day 1 year after myocardial infarction, regardless of previous antiplatelet therapy and the presence of interruptions in therapy.
Patients who started taking Brilinta at a dose of 90 mg 2 times / day during the acute period, after 1 year can continue therapy with Brilinta at a dose of 60 mg 2 times / day without interruption.
Before starting the use of the drug Brilinta (in combination with ASA), current antiplatelet therapy should be discontinued.
When transferring patients to the Brilint drug, the first dose should be prescribed 24 hours after taking the last dose of another antiplatelet drug.
Prematurely discontinuing any antiplatelet therapy, including the Brilint drug, may increase the risk of cardiovascular death or myocardial infarction as a result of the underlying disease. Premature discontinuation of the drug should be avoided. Breaks in therapy should also be avoided. A patient who has missed taking Brilint's drug should only take 1 tab. 60 mg (next dose) at the scheduled time.
Elderly patients do not need dose adjustment.
It is not necessary to adjust the dose of the drug in patients with impaired renal function. There is no available information on the treatment of patients on hemodialysis, therefore the Brilint drug is not recommended for patients of this group.
There have been no studies of the drug Brilinta in patients with severe liver dysfunction, the use of the drug in patients of this group is contraindicated. Information on the treatment of patients with impaired liver function of moderate severity is limited. No dosage adjustment is required for patients with mild or moderate hepatic impairment .
The safety and effectiveness of the Brilint drug in children and adolescents under the age of 18 according to an indication approved in adults have not been established.
Side effects
Brilique safety profile of the Brilint drug was evaluated in two phase 3 studies (PLATO and PEGASUS), which included more than 39,000 patients. The adverse reactions reported in these clinical studies are presented below.
In the PLATO study, patients who received the Brilint drug were more likely to discontinue therapy due to the development of adverse events than patients who received clopidogrel (7.4% compared with 5.4%).
In the PEGASUS study, the frequency of treatment discontinuation due to the development of adverse events was higher with Brilint than with ASA monotherapy (16.1% in the ticagrelor 60 mg + ASA group compared with 8.5% in the ASA monotherapy group).
The most commonly reported adverse reactions in patients taking ticagrelor were bleeding and shortness of breath.
Adverse reactions observed during clinical trials of the drug Brilint are described by systemic organ classes and frequency of development and are listed in decreasing order of severity. The frequency of adverse reactions is determined using the following conventions: very often (≥1 / 10), often (≥1 / 100, benign, malignant, and unspecified neoplasms (including cysts and polyps): infrequently - bleeding from a tumor .
